Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Concord Biotech Limited is an R&D-driven biopharmaceutical company that develops and manufactures fermentation-based active pharmaceutical ingredients (APIs), finished formulations and CDMO services, serving 70+ countries including regulated markets and maintaining over 140 DMFs and significant fermentation capacity across multiple Gujarat facilities.
Q3 FY26 performance showed revenue improvement with consolidated quarterly revenue of INR 278 crore (up 14% YoY) driven by a 24% jump in API sales, while 9MFY26 revenue remained lower at INR 729 crore due to timing-related headwinds and geopolitical/tariff disruptions which management describes as temporary.
Management received WHO‑GMP certification for the new injectable facility and quantified a peak revenue potential near INR 600 crore; they also set up Stellon Biotech in the US to commercialize Concord’s products directly, both actions materially expanding commercial channels and future revenue levers.
Normalized EBITDA margins remain strong at around 40% when excluding one‑off commercialization and subsidiary setup costs, but reported 9MF EBITDA margin declined to ~34% due to injectable commercialization and Stellon setup expenses; company maintains zero net debt and a cash/investment base to pursue organic and inorganic opportunities.
Pharmaceuticals & Biotechnology
Pharmaceuticals
14,076 Cr
Low Risk
53.9
34.1
1.3
7.0
2,143.95
987.05
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Concord Biotech Ltd (CONCORDBIO) is currently trading at 1,345.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Concord Biotech Limited is an R&D-driven biopharmaceutical company that develops and manufactures fermentation-based active pharmaceutical ingredients (APIs), finished formulations and CDMO services, serving 70+ countries including regulated markets and maintaining over 140 DMFs and significant fermentation capacity across multiple Gujarat facilities. Q3 FY26 performance showed revenue improvement with consolidated quarterly revenue of INR 278 crore (up 14% YoY) driven by a 24% jump in API sales, while 9MFY26 revenue remained lower at INR 729 crore due to timing-related headwinds and geopolitical/tariff disruptions which management describes as temporary. Management received WHO‑GMP certification for the new injectable facility and quantified a peak revenue potential near INR 600 crore; they also set up Stellon Biotech in the US to commercialize Concord’s products directly, both actions materially expanding commercial channels and future revenue levers. Normalized EBITDA margins remain strong at around 40% when excluding one‑off commercialization and subsidiary setup costs, but reported 9MF EBITDA margin declined to ~34% due to injectable commercialization and Stellon setup expenses; company maintains zero net debt and a cash/investment base to pursue organic and inorganic opportunities.
Over the past 52 weeks, Concord Biotech Ltd has traded between a low of ₹987.05 and a high of ₹2,143.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Concord Biotech Ltd has a market capitalization of approximately 14,074.02. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Concord Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 53.94 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 14,074.02 Cr, Concord Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Concord Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Concord Biotech Ltd is 53.94. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The stock gained after Concord Biotech announced USFDA approval for its ANDA for Tofacitinib tablets in 5 mg and 10 mg strengths.
The shares rose after Concord Biotech disclosed USFDA approval for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
Concord Biotech received USFDA approval for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
Concord Biotech received USFDA approval for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
Discovery themes featuring this stock
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
7
Neutral
2
Bullish
5
Bearish
8
Neutral
2
Bullish
36
Bearish
1
Neutral
0
Bullish
31
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
425.00 | 16,194 Cr | 90.35 | 4.14 | 0.00 | 5.05 | 5.47 | 2.62 | ||
846.10 | 15,091 Cr | 10.64 | 1.64 | 0.59 | 15.38 | 15.37 | 12.39 | ||
941.75 | 15,070 Cr | 37.82 | 2.12 | 0.52 | 5.62 | 6.41 | 2.56 | ||
735.50 | 14,447 Cr | 21.41 | 2.55 | 1.63 | 11.89 | 10.81 | 7.66 | ||
1345.30 | 14,074 Cr | 53.94 | 6.98 | 0.56 | 12.94 | 17.08 | 11.60 | ||
1024.85 | 12,543 Cr | 22.22 | 3.76 | 0.49 | 16.94 | 22.33 | 14.17 | ||
250.50 | 11,313 Cr | 27.07 | 3.74 | 0.36 | 13.82 | 17.37 | 10.88 | ||
| Median: 7 Co. | — | 846.10 | 14,447 Cr | 27.07 | 3.74 | 0.52 | 12.94 | 15.37 | 10.88 |
ANDA Approval
Concord Biotech received USFDA approval for its ANDA for Tofacitinib tablets (5 mg & 10 mg) for multiple autoimmune indications; U.S. market for both strengths estimated at ~US$500m, supporting US/international growth.
ANDA approval
Concord Biotech received US FDA approval for its ANDA for Tofacitinib tablets (5 mg and 10 mg) for multiple indications, enabling U.S. commercialization into an estimated ~$500m market.
Earnings Call Transcript
Transcript of Concord Biotech's Q4 & FY26 earnings call: FY26 faced procurement, geopolitical and regulatory headwinds that weighed on revenues, while regulatory approvals, injectable facility commissioning and new customer wins support optimism for FY27.
Earnings Call Transcript
Concord Biotech filed the transcript of its Q4 & FY26 earnings call (June 1, 2026) covering FY26 headwinds (geopolitics, supply chain, regulatory delays), operational updates, certifications, and FY27 outlook.
